Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Multicenter, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With B Cell Non-Hodgkin Lymphomas

NCT05400109 is registered in ClinicalTrials.gov with David Wald as lead sponsor.

NCT NCT05400109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05400109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Multicenter, Open Label Study to Evaluate the Safety of UF-KURE19 Cells in Patients With B Cell Non-Hodgkin Lymphomas
Lead sponsor
David Wald
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 26, 2023
Completion date
October 1, 2026
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non hodgkin lymphoma